cefiderocol
Selected indexed studies
- New Perspectives on Antimicrobial Agents: Cefiderocol. (Antimicrob Agents Chemother, 2021) [PMID:34031052]
- Cefiderocol. (Rev Esp Quimioter, 2022) [PMID:35488822]
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. (Lancet Infect Dis, 2021) [PMID:33058795]
_Worker-drafted node — pending editorial review._
Connections
cefiderocol is a side effect of
Sources
- New Perspectives on Antimicrobial Agents: Cefiderocol. (2021) pubmed
- Cefiderocol. (2022) pubmed
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. (2021) pubmed
- Cefiderocol: Clinical application and emergence of resistance. (2024) pubmed
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin. (2019) pubmed
- Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. (2021) pubmed
- Cefiderocol: A Siderophore Cephalosporin. (2020) pubmed
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. (2019) pubmed
- Cefiderocol. Summary and conclusions. (2022) pubmed
- Cefiderocol either in monotherapy or combination versus best available therapy in the treatment of carbapenem-resistant Acinetobacter baumannii infections: A systematic review and meta-analysis. (2024) pubmed